EUVIMEDOpdag EUVIMED
Crossref

Impact of HCV eradication on recurrence pattern and long‐term outcomes in patients with HCV ‐related hepatocellular carcinoma undergoing radiofrequency ablation

Kuo-Cheng Wu iD, I-Cheng Lee iD, Chen-Ta Chi, Chien-An Liu, Nai-Chi Chiu, Shao-Jung Hsu, Pei-Chang Lee, Chi-Jung Wu, Jiing-Chyuan Luo iD, Ming-Chih Hou, Yi-Hsiang Huang iD

Alimentary Pharmacology & Therapeutics · 2024-10 · 60 (7) · 940-952

DOI: 10.1111/apt.18199 ↗

At a glance

Journal article in Alimentary Pharmacology & Therapeutics, published online on 2024-08-07. Written by Kuo-Cheng Wu and 10 co-authors. Institution: Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan. Major MEDLINE topics: Carcinoma, Hepatocellular, Liver Neoplasms, Antiviral Agents, Neoplasm Recurrence, Local. Cited 12 times so far (Crossref); 39 references. Funded by: Ministry of Science and Technology, Taiwan, Taipei Veterans General Hospital, National Science and Technology Council.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

The benefits of HCV eradication on distinct recurrence patterns and long‐term hepatic outcomes in patients with hepatocellular carcinoma (HCC) undergoing radiofrequency ablation (RFA) remain uncertain. This study aims to assess the impact of HCV eradication on HCC recurrence patterns and long‐term hepatic outcomes after RFA and to identify predictors of recurrence in patients achieving sustained virological response (SVR).

Methods

We retrospectively enrolled 274 patients receiving RFA for HCV‐related HCC, including 73 and 88 patients treated with interferon‐based (IFN) and direct‐acting antivirals (DAA) therapy, respectively. We analysed factors associated with local tumour progression (LTP), distant recurrence, overall survival, and hepatic decompensation.

Results

SVR was achieved in 49.3% of patients undergoing IFN therapy and 93.2% of patients undergoing DAA therapy. HCV eradication was not associated with LTP but significantly correlated with reduced risk of distant recurrence (by DAA: hazard ratio (HR) = 0.449, p = 0.006), overall survival (by IFN: HR = 0.242, p < 0.001; by DAA: HR = 0.274, p < 0.001) and hepatic decompensation (by IFN: HR = 0.313, p = 0.004; by DAA: HR = 0.281, p < 0.001). The benefits of achieving SVR in terms of overall survival and hepatic decompensation remained significant in subgroups of patients with and without recurrence. Patients with SVR showed a significant decline in FIB‐4 score and a higher proportion of ALBI grade improvement. Among SVR patients, the IMbrave050 criteria predicted LTP but not distant recurrence, whereas the FIB‐4 score after SVR, rather than the baseline FIB‐4, predicted distant recurrence.

Conclusions

HCV eradication was associated with a significant reduction in distant recurrence, mortality and hepatic decompensation following RFA in patients with HCV‐related HCC.

Subjects

MeSH terms (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsAntiviral AgentsNeoplasm Recurrence, LocalRadiofrequency AblationSustained Virologic ResponseHumansMaleFemaleRetrospective StudiesMiddle AgedAgedTreatment OutcomeHepatitis C, ChronicHepacivirus

Substances

Antiviral Agents

Authors and institutions

  • Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Division of Gastroenterology and Hepatology, Department of Medicine, Keelung Hospital, Ministry of Health and Welfare, Keelung, Taiwan.
  • School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Department of Radiology, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Healthcare and Service Center, Taipei Veterans General Hospital, Taipei, Taiwan.

ORCID profiles: Kuo-Cheng Wu, I-Cheng Lee, Jiing-Chyuan Luo, Yi-Hsiang Huang

Funding

  • Ministry of Science and Technology, Taiwan
  • Taipei Veterans General Hospital
  • National Science and Technology Council

Cite

APA

Wu, K. C., Lee, I. C., Chi, C. T., Liu, C. A., Chiu, N. C., Hsu, S. J., Lee, P. C., Wu, C. J., Luo, J. C., Hou, M. C., & Huang, Y. H. (2024). Impact of HCV eradication on recurrence pattern and long‐term outcomes in patients with HCV ‐related hepatocellular carcinoma undergoing radiofrequency ablation. Alimentary Pharmacology & Therapeutics, 60(7), 940-952. https://doi.org/10.1111/apt.18199

Vancouver

Wu KC, Lee IC, Chi CT, Liu CA, Chiu NC, Hsu SJ, et al. Impact of HCV eradication on recurrence pattern and long‐term outcomes in patients with HCV ‐related hepatocellular carcinoma undergoing radiofrequency ablation. Alimentary Pharmacology & Therapeutics. 2024;60(7):940-952. doi:10.1111/apt.18199

BibTeX
@article{Wu2024,
  author = {Wu, Kuo-Cheng and Lee, I-Cheng and Chi, Chen-Ta and Liu, Chien-An and Chiu, Nai-Chi and Hsu, Shao-Jung and Lee, Pei-Chang and Wu, Chi-Jung and Luo, Jiing-Chyuan and Hou, Ming-Chih and Huang, Yi-Hsiang},
  title = {Impact of HCV eradication on recurrence pattern and long‐term outcomes in patients with HCV ‐related hepatocellular carcinoma undergoing radiofrequency ablation},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  volume = {60},
  number = {7},
  pages = {940--952},
  doi = {10.1111/apt.18199}
}
Start for free →